Inactive Instrument

All News TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from NASDAQ Composite Index	23-06-01	CI
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P Global BMI Index	23-06-01	CI
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P TMI Index	23-06-01	CI
Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.	23-05-31	CI
TCR2 THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-05-24	AQ
TCR2 Therapeutics : Merger Agreement - Form 8-K	23-05-23	PU
TCR-2 THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	23-05-12	AQ
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
TCR2 THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-11	AQ
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update	23-05-11	GL
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-05-08	GL
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-05-08	AQ
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR	23-04-26	BU
TCR-2 THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	23-04-04	AQ
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-04-03	GL
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-04-03	AQ
Mizuho Securities Downgrades TCR2 Therapeutics to Neutral From Buy, Adjusts Price Target to $1.72 From $20	23-03-24	MT
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating	23-03-23	MT
TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-23	AQ
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update	23-03-23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

All News

Filters